Opicapone

DRUG6 trials

Sponsors

Rabin Medical Center, Neurocrine Biosciences, Bial - Portela C S.A.

Conditions

Parkinson Disease

Phase 1

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

CompletedNCT03496870

Neurocrine BiosciencesParkinson Disease

Start: 2018-02-08End: 2018-07-02Updated: 2019-03-22

Phase 3

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

CompletedNCT01851850

Rabin Medical CenterParkinson Disease

Start: 2013-05-31End: 2016-05-24Updated: 2020-03-16

Phase 4

OpicApone Sleep dISorder

CompletedNCT04986995

Bial - Portela C S.A.Parkinson Disease

Start: 2021-06-09End: 2023-03-29Updated: 2025-03-12

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

CompletedNCT04990284

Bial - Portela C S.A.Parkinson Disease

Start: 2021-11-29End: 2023-04-04Updated: 2025-03-12

Unknown Phase

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

CompletedNCT03959540

Bial - Portela C S.A.Parkinson Disease

Start: 2020-04-28End: 2021-05-11Updated: 2021-10-04

Opicapone Treatment Initiation Open-Label Study

CompletedNCT04787965

Neurocrine BiosciencesParkinson Disease

Start: 2021-03-01End: 2022-08-04Updated: 2022-11-28

Related Papers

Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies.

2024-08-212 citations